Sun Pharmaceutical Industries Limited

Ranbaxy Laboratories, Inc.

Vinod Kumar Arora

Mohan Prasad

Naresh Kumar

Sumit Madan

Jyoti Srivastava

Vaibhav Dubey

Shashikanth P Isloor

Sudershan Kumar Arora

Rajesh Rao

Rathinasabapathy Venkateshwaran

Manisha Pandya

Vikas Jain

Jaiprakash Jaysingrao Bhelonde

Vyas M Shingatgeri

Monika Obrah

Sanjay Kumar Sharma

Rajinder K Jalali

Sanjay Kumar Motwani

Neeta Gupta

Simrata Bedi

Gour Mukherji

Harish Kumar Madan

Vinod George

Sandhya Goel

Vishnu Datta Maremanda

K K Janakiraman

Vasu Kumar Kakumanu

Subodh Deshmukh

Anju Bansal

Bhaskar Chauhan

Bhupendra Vashishta

Arno Appavoo Enose

Anupam Trehan

Puneet Tyagi

The present invention relates to a topical pharmaceutical composition comprising acitretin and a process for its preparation. It also relates to a method of treating skin disorders by administering said topical pharmaceutical composition.

Topical pharmaceutical composition of acitretin

The present invention relates to a topical solution comprising a retinoid or its pharmaceutically acceptable salts thereof and a process of preparing it.

Topical retinoid solutions

The present invention relates to a topical solution comprising a retinoid or its pharmaceutically acceptable salts thereof and process of preparing it.

Topical solution of isotretinoin

The invention relates to a topical pharmaceutical composition for burn treatment and microbial infections on human beings or animals. The pharmaceutical composition comprises 0.1% w/w to 1.0% w/w of an antimicrobial drug, i.e., silver sulfadiazine and 0.2% w/w antiseptic, i.e., chlorhexidine gluconate, wherein silver sulfadiazine is in nanonized form.

Topical pharmaceutical composition comprising nanonized silver sulfadiazine

The invention relates to a delayed release pharmaceutical composition of mesalamine comprising: a) granules comprising mesalamine or pharmaceutically acceptable salts thereof and a hydrophilic polymer; b) extragranular excipients; wherein the pharmaceutical composition is further coated with a single layer of polymer.

Delayed release pharmaceutical composition of mesalamine

The invention relates to stable parenteral formulations of tigecycline and process of preparation thereof, wherein the formulation comprises an edetate, a pH modifying agent or an antioxidant, such that the formulation remains stable for at least 45 hours.

Stable parenteral formulations of tigecycline

The field of the invention relates to stable dosage forms comprising spiro or dispiro 1,2,4-trioxolane antimalarials, or their pharmaceutically acceptable salts, prodrugs and analogues, and processes for their preparation. The water content of the dosage form is not more than 6.5% w/w.

Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials

A taste masked composition which comprises a bitter tasting drug, a combination of two enteric polymers comprising, a methacrylic acid copolymer and a phthalate polymer is described. The composition of the present invention is prepared by dissolving the active ingredient, the methacrylic acid copolymer and the phthalate polymer in a solvent and recovering the composition from the solution thereof.

Taste masked compositions

Growing community of inventors

Gurgaon, India

Vinod Kumar Arora